AN2 Therapeutics to Participate at Upcoming Investor Conferences
Get Alerts ANTX Hot Sheet
Join SI Premium – FREE
MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March.
Details of the events are as follows:
TD Cowen 45th Annual Health Care Conference
- Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Monday, March 3, 2025 at 2:30 pm ET, and members of management will be available for 1X1 meetings.
Leerink Partners Global Healthcare Conference
- Members of management will be available for 1X1 meetings on Wednesday, March 12, 2025.
A webcast of the Cowen Health Care Conference presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220323899/en/
COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
[email protected]
INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
[email protected]
Source: AN2 Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Destiny Tech100 Inc. Reports Second Quarter 2026 Results
- Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
- UpStart Investments Files for TSXV Conditional Approval
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share